% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Romanovsky:275438,
author = {E. Romanovsky and K. Kluck and I. Ourailidis and M. Menzel
and S. Beck and M. Ball and D. Kazdal and P. Christopoulos
and P. Schirmacher$^*$ and T. Stiewe and A. Stenzinger$^*$
and J. Budczies$^*$},
title = {{H}omogenous {TP}53mut-associated tumor biology across
mutation and cancer types revealed by transcriptome
analysis.},
journal = {Cell death discovery},
volume = {9},
number = {1},
issn = {2058-7716},
address = {London},
publisher = {Nature Publishing Group},
reportid = {DKFZ-2023-00761},
pages = {126},
year = {2023},
abstract = {TP53 is the most frequently mutated gene in human cancer.
While no TP53-targeting drugs have been approved in the USA
or Europe so far, preclinical and clinical studies are
underway to investigate targeting of specific or all TP53
mutations, for example, by restoration of the functionality
of mutated TP53 (TP53mut) or protecting wildtype TP53
(TP53wt) from negative regulation. We performed a
comprehensive mRNA expression analysis in 24 cancer types of
TCGA to extract (i) a consensus expression signature shared
across TP53 mutation types and cancer types, (ii)
differential gene expression patterns between tumors
harboring different TP53 mutation types such as loss of
function, gain of function or dominant-negative mutations,
and (iii) cancer-type-specific patterns of gene expression
and immune infiltration. Analysis of mutational hotspots
revealed both similarities across cancer types and cancer
type-specific hotspots. Underlying ubiquitous and cancer
type-specific mutational processes with the associated
mutational signatures contributed to explaining this
observation. Virtually no genes were differentially
expressed between tumors harboring different TP53 mutation
types, while hundreds of genes were over- and underexpressed
in TP53mut compared to TP53wt tumors. A consensus list
included 178 genes that were overexpressed and 32 genes that
were underexpressed in the TP53mut tumors of at least 16 of
the investigated 24 cancer types. In an association analysis
of immune infiltration with TP53 mutations in 32 cancer
subtypes, decreased immune infiltration was observed in six
subtypes, increased infiltration in two subtypes, a mixed
pattern of decreased and increased immune cell populations
in four subtypes, while immune infiltration was not
associated with TP53 status in 20 subtypes. The analysis of
a large cohort of human tumors complements results from
experimental studies and supports the view that TP53
mutations should be further evaluated as predictive markers
for immunotherapy and targeted therapies.},
cin = {HD01},
ddc = {610},
cid = {I:(DE-He78)HD01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37059713},
doi = {10.1038/s41420-023-01413-1},
url = {https://inrepo02.dkfz.de/record/275438},
}